Liver Transplantation for Hepatocellular Carcinoma Outperform Other Populations in the New Hepatitis C Era
Poster May 09, 2018
Robert Burk BS, Angel Alsina MD, Alexia Athienitis PhD, John Trendowski BS, Alejandro Delgado BS, Jacentha Buggs MD, Brenna Evans RN, Edson Franco MD, Christopher Albers MD, Nyingi Kemmer MD
Background: Long term results of HCC liver transplants (LTx) in the recent era of direct-acting antivirals (DAA) against hepatitis C (HCV) are not available. We aimed to examine the access, treatments and cure rates with DAA’s utilized in HCC LTx with HCV. Secondarily, we aimed to determine the long term impact of the Liver Cancer Program and DAA therapies on survival of HCC LTx.
Methods: A retrospective analysis of 4 eras of transplantation for HCC/HCV LTx at a single center: Era 1 (’97-2001), 2 (2002-06), 3 (2007-10), and Era 4 (2011-15). In 2011, utilization of first generation DAA’s began, as well as a fully revamped liver cancer program. By 2012, second generation DAA’s were used. All eras were examined for patients that died prior to reaching DAA’s (Era 4). Era 1 to 4 had 2, 20, 47 and 67 HCC/HCV patients, respectively. All DAA treatments in this study were post liver Tx. Kaplan Meier methodology, Log rank and Chi-square was utilized
Results: There were 136 HCC/HCV liver Tx out of 233 liver Tx for HCC during entire time period. More patients Era 3 (41/47=87%) vs. Era 1 and 2 (10/22= 45%) were able to reach the DAA era (p= 0.0002). More patients in Era 4 (22/67=32.8%) were treated with DAA’s than in Era 3 (8/47=17.7%) and in Era 2 (2/20= 10%, p= 0.04). [Era 3 vs 4, p=0.059]. More patients were cured in Era 4 (22/67= 32.8%) vs. Era 3 (7/47=14.8, p=0.03). Improvement across the 4 eras of liver Tx for HCC was statistically significant (Log Rank 0.0018). The 3-year survival of 89 patients in Era 4 was 87.3% compared to 68% for Era 3. Forty-nine patients have already reached that endpoint.
Conclusion: Conclusions: The superiority of Era 4 HCC liver Tx is impressive, with a 19% survival improvement. Decay after the first year was only 3.8% / year. This era coincides with the beginning of DAA’s and the revamped liver cancer program, both significantly improving survival. Contributions from Hepatitis C therapies on overall survival of HCC LTx are unquestionable. One third of HCV infected HCC patients were treated and cured. All (100%) were cured since 2011. However, other factors in the liver cancer program also contributed: better bridge therapies, adjuvant therapies, patient selection, among others. Hepatocellular carcinoma liver Tx recipients are outperforming other liver Tx recipients, and are comparable to HCV alone.
Characterization of a Type 2 diabetes-associated islet-specific enhancer cluster in STARD10 by genome editing of EndoC-βH1 cellsPoster
Genome-wide association studies (GWAS) have identified more than 100 genetic loci associated with type 2 diabetes. The majority of these are located in the intergenic or intragenic regions suggesting that the implicated variants may alter chromatin conformation. This, in turn, is likely to influence the expression of nearby or more remotely located genes to alter beta cell function. At present, however, detailed molecular and functional analyses are still lacking for most of these variants. We recently analysed one of these loci and mapped five causal variants in an islet-specific enhancer cluster within the STARD10 gene locus. Here, we aimed to understand how these causal variants influence b-cell function by alteration of the chromatin structure of enhancer clusterREAD MORE
Mass Spectrometry: From Imaging to Metabolic NetworksPoster
We show that network analysis of co-localized ions from mass spectrometry imaging data provides a detailed chemo-spatial insight into the metabolic heterogeneity of tumors. Furthermore, module preservation analysis between colorectal cancer patients with and without metastatic recurrence suggests hypotheses on the nature of the different local metabolic pathways.READ MORE
Young Adult Women’s Relationship Status and HPV Risk Perceptions: A Barrier to HPV Vaccination?Poster
Human papillomavirus (HPV) vaccine rates continue to be low in the United States. Young women ages 18-26 years are eligible for catch-up vaccination but previous research shows that relationships status and percieved risk may be barriers to HPV vaccination. The purpose of this quantitative study was to assess the association between relationship status and perceived risk for HPV among young adult women.READ MORE